NRG-GU015 ARCHER Trial Video. @NRGonc @HimanshuNagarMD @drjefstathiou

🚨ARCHER, a pivotal phase 3 bladder cancer trial led by our own @UroCancer in Metairie, is bringing world-class research to Louisiana. For our patients, clinical trials like ARCHER mean: -Access to cutting-edge therapies -Better outcomes for patients -Bringing world-class

Can’t miss #ESMO25 =>Practice-changing, Practice-informing and forward-looking data in all cancers ! @myESMO @MyriamChalabi @FAndreMD

⚾️ Scene outside Wrigley Field #Chicago after @cubs force a decisive game 5 in Milwaukee on Saturday https://t.co/xcfLMHUo5C

NRG-GU006 trial for post-prostatectomy radiation therapy. @DrSpratticus @caseccc joins @jmmrad @WashUMedRadOnc to present the NRG GU006/BALANCE trial results, demonstrating PAM50 molecular subtypes as the first prospectively validated predictive biomarker guiding hormone therapy

Mid-City homicide victim was father picking up child at daycare, NOPD says

APUC-6 and AR expression together are prognostic and possibly predictive in CHAARTED #ProstateCancer #ASTRO25 @ASTRO_org @AdamSharpMedOnc @Davicioni @JoshLangMD @DrRanaMcKay

First up NRG GU006 BALANCE trial showing significant improvement in PFS in recurrent prostate cancer with radiation and apalutamide! Also the first biomarker stratified prospectively validated use of HRT. @DrSpratticus #ASTRO25

🚀 Exciting results from the NRG GU006 trial! 🎉 Patients with luminal B prostate cancer saw significant benefits from adding apalutamide (APA) to salvage radiotherapy, making PAM50 the first validated predictive biomarker for hormone therapy in this context. @ASTRO_org

🎉 Congratulations @ejasonabel who will receive the KCA's Andrew C. Novick Award at #IKCSNA25! This award recognizes excellence in #kidneycancer urology care. Read more: https://t.co/ud1wtMFOZB

The High-Five Trial (NRG-GU013) is examining whether a shorter course of radiation at a higher dose is equally as effective in preventing the recurrence of cancer in pts with high-risk #prostatecancer as the standard course of radiation. https://t.co/9FZaIyHLgH @KHoffmanMD

City of New Orleans train to Chicago, Pequod’s Pizza , Beer, Wrigley ….good time.

🎯 Adaptive Radiation and Chemotherapy For Muscle Invasive Bladder Cancer (ARCHER) 🏹 This video highlights NRG-GU015: ARCHER, a phase III, patient-centric, bladder-sparing trial now open to accrual. The trial asks whether ultra-hypofractionated RT (SBRT) over 5 treatments with

Never forget.

Notre Dame brought out Shane Gillis 😭😭 https://t.co/r8an3KSUxK

NC med students: “I studied 16 years.” NC Health Systems: Cute. The guys from overseas are cheaper.

NRG-GU015, the "ARCHER" study, recently activated! We interviewed study PI @UroCancer and co-PI @HimanshuNagarMD on this phase 3 study of adaptive radiation and chemotherapy for muscle invasive #bladdercancer. Watch the full interview here: https://t.co/dqq2S2M3tz @DrPaulNguyen

🏹 Randomized Phase III Trial: Adaptive Radiation and Chemotherapy For Muscle Invasive Bladder Cancer (ARCHER) Congratulations to the NRG GU015 ARCHER study team led by @UroCancer and @HimanshuNagarMD for the recent activation and launch of this cutting-edge and patient-centric

Safety of combining radiotherapy with antibody-drug conjugates in advanced #UrothelialCarcinoma. @ndesai2005 @UTSWMedCenter joins @l_ballas @CedarsSinai sharing findings from a retrospective study examining whether these increasingly important treatments interact adversely with

PRESS RELEASE: NRG Oncology Opens New “ARCHER” Clinical Trial (NRG-GU015) Testing a Shorter Treatment Duration of Radiation Therapy for Muscle Invasive Bladder Cancer - Read more: https://t.co/quCNs5tMBj @UroCancer @HimanshuNagarMD @MSKCancerCenter